Nature is one of the most authoritative academic journals in the world, and is also considered by many scientists to be one of the highest temples of academic papers.

Many of the scientific research results that affect the industry are usually favored by Nature.

Middel's logic was very simple, he had heard that Origin Technologies' paper on symbiotic proteins had been submitted to Nature, but Nature did not have a bird paper, let alone published it.

If the symbiotic photosynthetic green leaf protein is really realized, it can really change the development process of biomedicine, and there is no reason why Nature should not publish it.

After interviewing Middell and others, the New York Times reported on the absurd scam of symbiotic photosynthetic green leaf protein under the headline "Technology is not science fiction."

The New York Times report is based on two things.

One is an on-site interview with Bloomage Hospital, and it was found that many patients with lung diseases are still waiting there and are not receiving the so-called symbiotic treatment.

The New York Times certainly won't be able to interview patients who have already been treated, because these patients are still under observation and won't be interviewed by reporters at all. In addition, the production of commensal bacilli is not large, and it cannot meet the needs of a large number of patients to be treated.

The second is that the international mainstream academic community scoffs at the technology of symbiotic photosynthetic green leaf protein, and does not even bother to comment on it. In Xia, only a third-rate academic journal published this paper, which is enough to show that the technology is unreliable.

Like the New York Times and other Western media outlets that have long reported on Xia Guo's bias, this article costs most of the West to talk after tea and dinner.

But the Chinese version of the New York Times report was different, with the title "A large number of patients waiting for new technology treatment", and the content was also very neutral, like describing Zhang San's visit to Li Si's house for dinner.

Look, the media also needs to be just right.

In addition to the New York Times, a number of tech columnists have also begun to write articles to attack the illusion of symbiotic proteins.

After all, everyone wants to have a good meal, and symbiotic protein is a rare topic at present, who do you write if you don't write?

Zhou Xiao didn't have time for idle talk, nor did he have time to read the New York Times report.

[Science and technology products: symbiotic photosynthetic green leaf protein. monopoly value, urban 17.3%; Aversion value, 3.2% in the city. 】

Symbiotic proteins have formed a wide influence in the domestic medical community, and the monopoly value cannot increase much before the scale of treatment is expanded.

At present, the monopoly value is much higher than the aversion value, and Zhou Xiao's choice is also very simple, continue to expand the influence of this technology.

It can not only cure diseases and save people, but also increase monopoly value, and also make money, which is also a win-win choice.

The final cost of the symbiotic protein treatment is also calculated.

Chen Hao took a stack of materials and drove from the factory to the headquarters to report the situation to Zhou Xiao.

Chen Hao has become the team leader of the life science laboratory and has realized the value of his life.

He now thinks back to what Zhou Xiao said when he first joined Origin Technology, and sure enough, not a single word was a fart, and it was all realized.

Chen Hao handed the information to Zhou Xiao and said: "Mr. Zhou, if you don't calculate the investment in the early stage, only calculate the cost of production, preservation and transportation of symbiotic bacteria, which is about 400 yuan per cubic centimeter. ”

Chen Hao added: "Since our production line is limited now, all strains can not get effective profits, and the cost will be greatly reduced after the completion of the new science and technology zone plant in the future." ”

Zhou Xiao estimated the cost, 400 yuan per cubic centimeter, calculated according to the average person's transplant of 200 to 300 square centimeters, the cost of a treatment is 80,000 to 120,000 yuan, which is the cost price of Origin Technology.

Zhou Xiao has to calculate not only the cost, but also the profit.

Origin Technology must not make money with a clear conscience for domestic patients, but before large-scale mass production, it must be 20% higher than the cost to maintain the normal operation of the company and the subsequent production increase, expansion and scientific research.

What's more, Origin Technology still has a huge upfront investment, and this investment must be slowly recovered.

In this way, the price is 480 yuan per cubic centimeter, and the total cost is about 96,000 to 144,000.

The cost of treatment in the hospital will rise, and the cost should be around 200,000.

200,000 yuan, all of which depend on the patient's own expense.

200,000 is completely affordable for patients with better family backgrounds, and it is not a matter at all.

But how many of those patients who suffer from pneumoconiosis and interstitial pneumonia have good family conditions?

According to official statistics, there are about 6 million pneumoconiosis patients in Xia Guo.

Most of these 6 million are low-level laborers, engaged in high-dust, high-pollution industries, with meager salaries, and they have to support their families with this money, and it is difficult to get 20,000 yuan, where is there 200,000 yuan for treatment.

Zhou Xiao frowned and paced back and forth in the office.

If patients can't afford it, the therapeutic technology of symbiotic protein will not be able to cover and promote.

It is not a question of whether to make money or not, it is a question of whether the monopoly value cannot meet the requirements and cannot complete the task.

If the panel has been stuck in the symbiotic protein, Zhou Xiao will not! Often! No! Open! Heart!

The question is how to make this technology accessible to patients and not lose money at Origin.

The way Zhou Xiao can think of is crowdfunding!

Mobilizing social resources to help patients can reduce the burden on patients and popularize treatment techniques.

Crowdfunding needs to cooperate with some disease crowdfunding treatment companies or even insurance companies, so that the other party can include the symbiotic treatment in the scope of crowdfunding treatment, but it depends on whether the other party has relevant intentions.

Just when Origin Technology contacted some crowdfunding platform companies, Dean Peng of the Jiangcheng People's House found Zhou Xiao.

Because of the establishment of the Oasis Hair Transplant Center, the income and influence of Jiangcheng People's Hospital have increased a lot.

But as a general hospital, how could President Peng be willing to just let Jiangcheng People's Hospital become a simple hair transplant center?

Jiangcheng People's Hospital and Origin Technology have cooperated for a long time, and now he sees that Origin Technology has put a revolutionary treatment technology such as symbiotic protein in Bloomage Hospital in Rongcheng instead of Jiangcheng Hospital, and he feels bad in his heart.

This time I came to visit in person, hoping to create a more professional respiratory medicine department.

The reason given by Dean Peng is also very convincing, "Jiangcheng is an old industrial city, in terms of the number of pneumoconiosis patients, Jiangcheng ranks first, so that patients can go to Rongcheng at the headquarters of the home treatment headquarters, okay?" ”

Zhou Xiao is embarrassed, there are many pneumoconiosis patients, this is worth bragging?

Zhou Xiao originally planned to expand the scope of influence of symbiotic protein therapy, and of course she was willing to cooperate with Jiangcheng People's Hospital, and also proposed her own cooperation plan.

Jiangcheng People's Hospital and Origin Technology jointly established a respiratory medicine treatment center.

The center is under the jurisdiction of the hospital, and Origin Technology provides products and sends technical instructors to guide doctors in treatment.

In addition to guidance, the main purpose of Zhou Xiao's technical staff is to try adjuvant therapy for lung cancer patients, which is still a gap in the current clinical trials.

But when Zhou Xiao came up with the treatment cost of symbiotic protein, Dean Peng was really embarrassed.

"In this way, it costs 200,000 yuan for treatment, and the symbiotic protein has just been treated in clinical practice, and it is not included in the medical insurance, and the patient pays more than 200,000 yuan...... I'm afraid many people can't afford it. ”

At this moment, Wang Yulan replied to the message.

Several large crowdfunding platforms have said that pneumoconiosis, interstitial pneumonia, lung cancer, etc. are all within the scope of crowdfunding, and they don't care how the hospital treats them.

But here comes the problem again, crowdfunding takes time, and it also requires all kinds of harsh terms (retweet times, exposure time, etc.).

For patients who are racing against their lives, I am afraid that if there is not enough money, everyone will be gone.

In addition, those workers who live at the bottom may not be able to use smartphones, let alone know what crowdfunding is.

Peng Yufei also felt that it would be unreliable to pin all his hopes on crowdfunding for treatment.

The two of them thought of a way.